Lumos Pharma, Inc. Company profile
About Lumos Pharma Inc
Lumos Pharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying, acquiring, developing and commercialization of products, and therapies for people with rare diseases. The Company's lead product candidate is LUM-201, a therapy for pediatric growth hormone deficiency (PGHD) and other rare endocrine disorders. LUM-201 stimulates growth hormone (GH) through the GH secretagogue receptor. Its product provides a differentiated mechanism of action to treat rare endocrine disorders by increasing the amplitude of endogenous and pulsatile GH secretion. LUM-201 is an orally administered small molecule, which is a GH secretagogue for rare endocrine disorders where injectable recombinant human growth hormone (rhGH) is approved. The Company’s pipeline features development programs in rare diseases associated with growth hormone deficiencies.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Lumos Pharma Inc revenues increased 37% to $230K. Net loss applicable to common stockholders increased from $6.3M to $30.4M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Other income (expense), net decrease of 96% to $269K (income), Interest Income decrease of 94% to $12K (income).
Equity composition
Common Stock $0.01 Par, Shares authorised and o/s after the offering: 38,833,334M auth, 18,021,913 issd. Insiders own approx. 38.90%(after the offering). IPO:TBA
Latest shares articles
![](https://img.capital.com/imgs/articles/384x2000x0/1350x880_-HP-_Newsquawk-light_1.png)
![Lloyds share price forecast: An attractive dividend stock?](https://img.capital.com/imgs/articles/384x2000x0/Hero-image-bank_1.png)
![Exterior of Infosys headquarters](https://img.capital.com/imgs/articles/384x2000x0/shutterstock_2035197281_0_0.jpg)
![Tesla logo atop of a Tesla Dealership illuminated at night.](https://img.capital.com/imgs/articles/384x2000x0/shutterstock_1494516293_0.jpg)